Study of two drugs for myelofibrosis with prior treatment
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a combination of two medications, ropeginterferon alfa-2b and ruxolitinib, for people with myelofibrosis whose spleen has not shrunk enough or has grown back while on ruxolitinib. The goal is to see if adding the newer drug can improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a confirmed diagnosis of overt myelofibrosis (primary or related to another blood disorder).
- Your disease must be at intermediate-1, intermediate-2, or high risk.
- Your previous treatment with ruxolitinib did not shrink your spleen enough or your spleen grew back after initial improvement.
- You have adequate blood counts (platelets, neutrophils) and a low number of blast cells in your blood.
- You cannot have used interferon medications before or have certain eye, immune, or mental health conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (pelabresib and ruxolitinib) for people with myelofibrosis whose spleen is enlarged and who have bothersome symptoms. It aims to see if adding pelabresib to standard care helps control the disease better.
This study tests an experimental pill called PRT12396 for people with myeloproliferative neoplasms (MPN). It aims to see if the drug is safe and helps control the disease.
This trial tests a combination of two oral medications for people with myelofibrosis, a type of bone marrow cancer. It may be an option if you have not been helped by standard JAK inhibitor therapy or if you have never tried one.
This trial tests whether adding a drug called interferon alfa-2b to the standard treatment ruxolitinib can help people with myelofibrosis. It may reduce spleen size and improve blood counts.
This trial tests an experimental drug called PMD-026 for people with myelofibrosis that has not responded well to a JAK inhibitor (like ruxolitinib). The goal is to see if PMD-026 can help reduce symptoms and spleen size.
This Phase 2 trial studies ropeginterferon alfa-2b (a type of interferon medicine) in adults with early, lower-risk myelofibrosis. The goal is to see if it can control the disease better or improve outcomes with an acceptable safety profile.
Hear when a new Primary Myelofibrosis (PMF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.